25 36

Cited 0 times in

Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B

DC FieldValueLanguage
dc.contributor.author김경현-
dc.date.accessioned2020-12-23T06:03:06Z-
dc.date.available2020-12-23T06:03:06Z-
dc.date.issued2020-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181156-
dc.description.abstract만성 B형 간염에서 근감소증은 간섬유화와 관련이 있다고 알려져 있습니다. 우리는 항바이러스제 치료하는 동안 간섬유화 변화와 근윤량 변화와의 인과관계에 대해 알아보았습니다. 2015년과 2018년 사이에 2회이상의 체지방검사를 받은 만성B형간염 환자를 대상으로 간섬유화스캔을 이용하여 섬유화 정도를 측정하였고 체지방검사를 이용하여 근육량을 측정하였습니다. 첫번째 체지방검사와 마지막 체지방검사와의 평균 간격은 19.0개월이며 의미있는 간섬유화는 간탄성도가 8kPa이상으로 정의하였습니다 연구 집단(남성 252명, 여성 163명)의 평균 연령은 55.9세 였습니다. 223명(53.7%)의 참가자가 항바이러스제 치료를 받았고 192명 (46.3%)의 참가자는 항바이러스제 치료를 받지 않았습니다. 항바이러스제 치료동안, 항바이러스제 치료 집단은 근육량이 21.16kg에서 21.00kg으로 유의하게 감소하였으며 (P=0.01), 항바이러스제 치료를 받지 않은 집단은 20.77kg에서 20.64kg으로 유의한 차이가 없었습니다 (P=0.134). 의미있는 간섬유화 환자 중에서 근육량 변화를 살펴보면, 항바이러스제 치료집단에서 근육량이 20.73kg에서 20.54kg으로 유의하게 감소하였으며 (P=0.037), 반면에 항바이러스제 치료하지 않은 딥단은 21.39kg에서 21.07kg으로 유의미한 차이는 없었습니다(P=0.097). 항바이러스제 치료를 하는동안 근육량의 유의한 감소가 있으므로 근육량을 유지하기위한 노력이 필요합니다. Sarcopenia is associated with significant liver fibrosis in patients with chronic hepatitis B (CHB). We investigated the dynamic association between hepatic fibrosis and changes in appendicular skeletal muscle mass during antiviral therapy (AVT). Patients with CHB who underwent paired liver stiffness measurements between 2015 and 2018, using transient elastography to assess fibrotic burden and bioelectrical impedance analysis to assess appendicular skeletal muscle mass (ASMM), were recruited retrospectively. The mean time interval between two bioelectrical impedance analyses was 19.0 months. Significant liver fibrosis was defined as liver stiffness ≥ 8 kPa. The mean age of the study population (252 men and 163 women) was 55.9 years. Among all participants, 223 (53.7%) received AVT (AVT group), whereas 192 (46.3%) did not receive AVT (no AVT group). During AVT, ASMM decreased significantly in the AVT group (from mean 21.16 to 21.00 kg, P=0.01) but showed no significant change in the no AVT group (from mean 20.77 to 20.64 kg, P=0.134). In the subgroup with significant liver fibrosis (66 and 42 participants with and without AVT, respectively), ASMM decreased significantly in the AVT group during AVT (from mean 20.73 to 20.54 kg, P=0.037) but showed no significant change in the no AVT group (from mean 21.39 to 21.07 kg, P=0.097). ASMM was significantly decreased during AVT. Thus, efforts should be made to maintain ASMM in patients with CHB receiving AVT.-
dc.description.statementOfResponsibilityopen-
dc.publisherGraduate School, Yonsei University-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleAssociation between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B-
dc.title.alternative만성B형간염에서 항바이러스제 치료로 인한 간섬유화 변화와 근육량 변화와의 관계-
dc.typeThesis-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDepartment of Medicine-
dc.description.degree석사-
dc.contributor.alternativeNameKyung Hyun Kim-
dc.type.localThesis-
Appears in Collections:
1. College of Medicine (의과대학) > Others (기타) > 2. Thesis

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.